Fig. 1From: Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancersa (5x) c (20x): H&E staining in ovarian serous carcinoma metastatic to the brain with the corresponding negative AR immunoreaction (b, 5x) and focal and weak AR expression (d, 20x) in primary tumor cells. e (5x), g (20x): H&E staining in control cases of ovarian carcinoma with strong and diffuse AR expression (f, h: 5x and 20x respectively)Back to article page